Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 0.34 |
| ▸ | GSK3B | P49841 | 5/20 | 0.34 |
| ▸ | CDK1 | P06493 | 3/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21363699 | 0.74 | TDP1 (0.33) | ALDH1A1 | |
| SCHEMBL24614004 | 0.70 | SMN1; SMN2 (0.39) | GSK3AGSK3BCDK1CCNB1CDK5 | |
| SCHEMBL21363621 | 0.68 | NOTUM (0.37) | GSK3AGSK3BCDK1CCNB1CDK5 | |
| SCHEMBL22477648 | 0.68 | ALDH1A1 (0.41) | GSK3AGSK3BCDK1CCNB1CDK5 | |
| SCHEMBL12411008 | 0.67 | MEN1 (0.45) | GSK3AGSK3BCDK1CCNB1MEN1 | |
| SCHEMBL7014104 | 0.66 | PRKCI (0.40) | — | |
| SCHEMBL22477750 | 0.65 | GSK3A (0.39) | GSK3AGSK3BCDK1CCNB1CDK5 | |
| SCHEMBL21363623 | 0.64 | TRPA1 (0.38) | GSK3AGSK3BCDK1CCNB1CDK5 | |
| SCHEMBL12535705 | 0.63 | PDPK1 (0.49) | ALDH1A1 | |
| SCHEMBL20097140 | 0.63 | GDA (0.62) | MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | GSK3A 1508/4885GSK3B 1325/4885CDK1 859/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | GSK3A 1508/4885GSK3B 1325/4885CDK1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.